Consort Partners PR

6K posts

Consort Partners PR banner
Consort Partners PR

Consort Partners PR

@consortpartners

Consort Partners is a full-service agency founded in 2004 comprised of a unique blend of PR, marketing and journalism. We specialize in tech, biotech, & fintech

SF, Toronto, Boston, London Katılım Mayıs 2009
508 Takip Edilen500 Takipçiler
Consort Partners PR retweetledi
etn.
etn.@etnshow·
Michele Catasta (@pirroh) President of Replit (@Replit) says "AGI for vibe-coding is coming earlier than 2028": "I would expect by the end of 2026, a lot of the core functionalities that models and agents have to have, in order to become very good vibe coding workhorses, will be there". "Literally the bottleneck would become grit, determination, if you want to take the time and, you know, invest a bit of money to make it happen". "No vibe coding tool today is absolutely perfect... but the amount of creativity that they unleash is second to none."
Amjad Masad@amasad

Software isn’t merely technical work anymore. It’s creative. Introducing Replit Agent 4. The first AI built for creative collaboration between humans and agents. Design on an infinite canvas, work with your team, run parallel agents, and ship working apps, sites, slides & more.

English
9
28
89
40.7K
Consort Partners PR retweetledi
Amjad Masad
Amjad Masad@amasad·
Software isn’t merely technical work anymore. It’s creative. Introducing Replit Agent 4. The first AI built for creative collaboration between humans and agents. Design on an infinite canvas, work with your team, run parallel agents, and ship working apps, sites, slides & more.
English
598
678
6.7K
2.9M
Consort Partners PR retweetledi
TBPN
TBPN@tbpn·
"Internally, we don't set ARR metrics." - Replit CEO @amasad Amjad says focusing on ARR is "optimizing for the wrong thing." Instead, they look at metrics like sentiment and how much money their customers are making: "In the age of AI, I don't think about ARR the same way a SaaS business does, because you're selling tokens. You can push a bug and get better ARR because [customers] are spending more tokens." "We're increasingly looking at how much money people are generating when they're building a business with Replit, because now you can hook in Stripe and other payment providers." "When people get angry, they'll tell the agents they're angry. We look at that a lot." "It's really about what you measure. We're trying to measure the quality of the output, as opposed to whatever ARR metric there is."
English
18
13
277
48K
Consort Partners PR retweetledi
Richard Nieva
Richard Nieva@richardjnieva·
New: Replit has raised $400 million at a $9 billion valuation, and is releasing its new coding agent. The goal is to make vibe coding more like you’re doodling on a white board. Paul Graham, an early investor, thinks it will “redefine” the term. forbes.com/sites/richardn…
English
6
20
79
44.6K
Consort Partners PR retweetledi
Shernaz Daver
Shernaz Daver@shernazdaver·
From the kid in Jordan to the cover of Forbes -- a journey is worth a thousand stories! Having known @amasad for a few years and watching him make the tough decisions to build what @Replit is today has been amazing! @pirroh @HayaOdeh
Richard Nieva@richardjnieva

New: Replit has raised $400 million at a $9 billion valuation, and is releasing its new coding agent. The goal is to make vibe coding more like you’re doodling on a white board. Paul Graham, an early investor, thinks it will “redefine” the term. forbes.com/sites/richardn…

English
1
6
40
9.8K
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
🚨 ICYMI: We're partnering with @YaleCancer on the pivotal CATE clinical trial. 🎯 Using NeXT Personal® to identify the earliest molecular signs of recurrence in patients with HR+/HER2- #BreastCancer ahead of imaging. 💊 Patients testing positive get preemptive elacestrant treatment with the goal to eliminate cancer before it becomes metastatic. Led by Dr. @MariyaRozenblit & Dr. @maryam_lustberg - this novel ctDNA-guided study (prospective, multi-center) is aimed at improving outcomes in patients with HR+/HER2- breast cancer (over 70% of all cases). 💪 📄Press Release: bit.ly/4grSkT0 📰 In the News: bit.ly/4pwujym #PrecisionOncology #ctDNA #ClinicalTrials
English
0
5
9
1.2K
Consort Partners PR retweetledi
The Index Podcast
The Index Podcast@theindexshow·
🔥 New Index drop! Host @afkehaya joins VPs Rick Johanson & Dan Peng @ArbitrumPlay to dive into how AGV's VC model is backing the next wave of game devs. Project Easy Mode offers: - Support beyond capital - Flexibility for indie teams - Tools to launch + grow Watch now!
English
26
70
1.3K
50.5K
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
📑 Check out this piece in National Geographic Health that highlights circulating tumor DNA (ctDNA) blood tests, such as NeXT Personal®, which can detect cancer recurrence earlier than traditional imaging scans. 🧬 NeXT Personal, an ultrasensitive ctDNA test, can detect very small traces of cancer in the blood helping oncology care teams plan personalized courses of action for their patients. Read the article for more information: on.natgeo.com/45RcdQm #PrecisionOncology #Diagnostics #ctDNA #PersonalizedMedicine #WGS #Genomics
English
1
3
10
1.6K
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
“The fact that we’ve seen every single recurrence being detected with ctDNA before clinical recurrence, and the fact that we haven’t seen any recurrences in patients who have surveillance samples that are negative is really impactful to say that [NeXT Personal®] is a test that you can trust.” We highlighted strong 💪 interim analysis results from the VICTORI study led by Dr. @jonathanloree's team at @BCCancer and presented by Dr. @emma_titmuss at AACR. These results showcased the ability of our ultrasensitive circulating tumor DNA (#ctDNA) test, NeXT Personal®, in detecting early signs of residual or recurrent #ColorectalCancer. Watch the video to learn more about these results. 📊 #PrecisionOncology #Diagnostics
English
0
3
11
1.6K
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
🧬 @LucCabelMD highlights key takeaways from the SCANDARE trial (#TripleNegativeBreastCancer) in which detection with NeXT Personal®, an ultrasensitive circulating tumor DNA (ctDNA) test, improved prognostication in early-stage triple negative breast cancer (TNBC) post-neoadjuvant treatment. The interim results of this 86-patient cohort included: • 100% baseline sensitivity - ctDNA was detected in 100% (84/84) of samples before start of treatment • Patients with ctDNA detected post-NAC were ~36 times more likely to have a distant relapse than patients with undetectable ctDNA. • ctDNA detection status post-NAC identified a subset of patients who did not achieve pCR but had significantly improved distant-recurrence-free-interval (DRFI), demonstrating the importance of ctDNA for improving stratification. • Integration of ctDNA and pCR status was highly prognostic and identified ctDNA-/non-pCR patients who had good outcomes • Among patients without pCR (non-pCR), ctDNA negative patients were 93% less likely to relapse than ctDNA positive patients. • Majority (>50%) of all ctDNA detections were in the ultrasensitive range below 100 parts per million (PPM) Watch the video to learn more. #PrecisionOncology #BreastCancer #TNBC #Diagnostics #UltrasensitivityMatters
English
0
2
8
750
Consort Partners PR retweetledi
Opentrons
Opentrons@opentrons·
Automating NGS with Targeted Enrichment using the new Flex High-Throughput Workstation 🧬🧪 📅 June 18 · 12PM ET | 9AM PT | 5PM GMT 🎥 Live demo 📊 Real-world data 📦 Automated tip + plate handling 🧠 End-to-end enrichment protocol automation Secure your spot → hubs.ly/Q03qWrYh0
Opentrons tweet media
English
0
1
0
142
Consort Partners PR retweetledi
Khosla Ventures
Khosla Ventures@khoslaventures·
20 years of building and beyond
English
19
13
70
21.4K
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
🚨NEW results from #ASCO25: Our ultrasensitive NeXT Personal® #ctDNA blood test detected cervical cancer relapse up to ~16 months ahead of imaging in a cohort of 186 patients with locally advanced #CervicalCancer in latest CALLA phase 3 study analysis. Key findings: • Detection of ctDNA following chemoradiotherapy (CRT) was independently prognostic of patient outcomes. • Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. • Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. • High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. Read the press release for further details: bit.ly/3SBUcO6. Check out the publication here: bit.ly/3ZPjb4j.
English
0
2
9
877
Consort Partners PR retweetledi
Personalis, Inc.
Personalis, Inc.@PersonalisInc·
Day 2 at #ASCO25! 🎬 Take a look inside our booth #31137 where we're showcasing the power of ultrasensitive ctDNA detection with NeXT Personal®. Still time to catch our presentations today & tomorrow: 🗣️ TODAY PM at Arie Crown Theatre: Dr. Natasha Hunter - initial data from PREDICT-DNA breast cancer trial 🗣️ TOMORROW AM at S100a: Dr. Jyoti Mayadev - CALLA trial in cervical cancer 📋 TOMORROW AM-12:00 PM in Poster Hall A (552/145): Dr. Luc Cabel - TNBC post-NAC findings 📋 TOMORROW -4:30 PM in Poster Hall A (2561/208): Dr Charles Abbott - Immunotherapy predictors in advanced cancer Stop by booth #31137 to partner #PrecisionOncology #ctDNA #MRD #RecurrenceDetection #breastcancer #cervicalcancer #immunotherapy @OlgaAlexeeva16
English
1
2
16
1.7K